Stockreport

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain [Yahoo! Finance]

Dogwood Therapeutics, Inc.  (DWTX) 
PDF - The overall study dropout rate of ~4.4% is far below rates typically observed with other FDA approved chronic pain medicines - ATLANTA, Dec. 22, 2025 (GLOBE NEWSWIR [Read more]